Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of N-acetylcysteine on Hydrogen Sulfide in CKD
NCT01232257Phase 3Completed
- Sponsor
- A.C. Abrahams
- Start
- Jul 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of acetylcysteine in chronic kidney disease (CKD) and end stage renal disease (ESRD) (4 arms), sponsored by A.C. Abrahams. Primary endpoint: Hydrogen sulfide at 48 hours. Started Jul 2011; status: completed.
02
Drugs
acetylcysteine
03
Conditions
chronic kidney disease (CKD)end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT01232257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01232257.